Embedded Files
PHARMAFORGE
Accelerating biopharmaceutical development by
enabling high-throughput experimentation
Description of the project
Description of the project
Belgium and the Netherlands are European leaders in biopharma, yet thousands of severe and rare diseases still lack effective treatments. At the same time, companies face growing challenges: slow and risky drug development, high infrastructure costs, and a persistent shortage of skilled talent.
PHARMAFORGE brings together top-tier Flemish and Dutch partners to change this. By building a shared high-throughput innovation platform and investing in next‑generation talent, PHARMAFORGE aims to speed up the entire drug development process - from discovery to production. PHARMAFORGE is an interreg multipartner project uniting the biopharma industry on the Flanders - South Netherlands border and funded by the European union.
Goals of the project
Goals of the project
The ultimate goal of PHARMAFORGE is to enhance the competitiveness, innovative capacity and sustainability of the pharmaceutical industry in the cross-boarder region and within the European Union.
To this end, the project has three objectives:
Gap analysis
Gap analysis
Conducting a gap analysis in Flanders and South Netherlands to identify gaps in the biopharmaceutical R&D landscape regarding infrastructure and human capital.
Open Access Labs (OAL)
Open Access Labs (OAL)
Provide better access to high-throughput experimentation expertise and infrastructure through the realization of the PHARMAFORGE innovation platform.
Lifelong Learning (LLL)
Lifelong Learning (LLL)
Access to a unique lifelong learning platform for targeted talent development focused on drug development and production.
Project Partners
Project Partners
Funded by the European Union
Funded by the European Union
This project has received funding from the European Union’s Interreg Vlaanderen-Nederland programme Interreg VI under project code Int6A066 – PHARMAFORGE.
Co-Financed by:
Co-Financed by:
Page updated
Google Sites
Report abuse